MDT discussions on the rationale for using GLP-1 as a therapeutic target in T2D

14/04/2022 13 min Episodio 103
MDT discussions on the rationale for using GLP-1 as a therapeutic target in T2D

Listen "MDT discussions on the rationale for using GLP-1 as a therapeutic target in T2D"

Episode Synopsis

touchMDT for touchENDOCRINOLOGY
Listen to key experts from a multidisciplinary team review the rationale for using GLP-1 as a therapeutic target in T2D and provide an overview of GLP-1 RA based therapies 
The multidisciplinary team
Primary Care Physician: Dr Kevin Fernando, Berwick, UK
Endocrinologist: Prof. Dr med. Michael Nauck, Bochum, Germany

This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Novo Nordisk A/S. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchendocrinologyime.org/mdt-integrating-glp1ras-t2d-management-from-pcp-to-patient/
 

More episodes of the podcast touchPODCAST